Literature DB >> 29067707

Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Maura Nicolosi1, Mythri Mudireddy1, Rangit Vallapureddy1, Naseema Gangat1, Ayalew Tefferi1, Mrinal M Patnaik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29067707     DOI： 10.1002/ajh.24952

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Authors:  Andrew T Kuykendall; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

3.  Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis.

Authors:  Azka Tasleem; Janet Roepke; Salahuddin Siddiqui
Journal:  EJHaem       Date:  2021-10-20

4.  Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia.

Authors:  Vera Adema; Jack Khouri; Ying Ni; Heesun J Rogers; Cassandra M Kerr; Hassan Awada; Yasunobu Nagata; Teodora Kuzmanovic; Anjali S Advani; Aaron T Gerds; Sudipto Mukherjee; Aziz Nazha; Yogen Saunthararajah; Yazan Madanat; Bhumika J Patel; Francesc Solé; Steffan T Nawrocki; Jennifer S Carew; Mikkael A Sekeres; Jaroslaw P Maciejewski; Valeria Visconte; Hetty E Carraway
Journal:  Leuk Lymphoma       Date:  2020-11-03

Review 5.  Causes and Pathophysiology of Acquired Sideroblastic Anemia.

Authors:  Juan Jose Rodriguez-Sevilla; Xavier Calvo; Leonor Arenillas
Journal:  Genes (Basel)       Date:  2022-08-30       Impact factor: 4.141

6.  The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Authors:  Tamara K Moyo; Jason H Mendler; Raphael Itzykson; Ashwin Kishtagari; Eric Solary; Adam C Seegmiller; Aaron T Gerds; Gregory D Ayers; Amy E Dezern; Aziz Nazha; Peter Valent; Arjan A van de Loosdrecht; Francesco Onida; Lisa Pleyer; Blanca Xicoy Cirici; Raoul Tibes; Klaus Geissler; Rami S Komrokji; Jing Zhang; Ulrich Germing; David P Steensma; Daniel H Wiseman; Michael Pfeilstöecker; Chiara Elena; Nicholas C P Cross; Jean-Jacques Kiladjian; Michael Luebbert; Ruben A Mesa; Guillermo Montalban-Bravo; Guillermo F Sanz; Uwe Platzbecker; Mrinal M Patnaik; Eric Padron; Valeria Santini; Pierre Fenaux; Michael R Savona
Journal:  BMC Cancer       Date:  2022-09-24       Impact factor: 4.638
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.